The Impact of Chemotherapy on the Lymphatic System in Thoracic Oncology

Antonio Passaro, Patrizia Trenta, Davide Conte, Giuseppe Campennì, Angelina De Benedetto, Enrico Cortesi

Research output: Contribution to journalArticlepeer-review


Non-small-cell lung cancer remains the leading cause of cancer-related mortality in the United States and Europe. Most patients are diagnosed with metastatic disease for which chemotherapy remains the cornerstone of treatment. In non-metastatic disease, surgery is the most potentially curative therapeutic option, but its outcome is still poor, in particular for patients with lymph node involvement. Therefore, several randomized adjuvant/neoadjuvant trials using chemotherapy and/or radiotherapy investigated the possibility of increasing the overall survival of patients with surgically treated lung cancer. The findings are reviewed in this article.

Original languageEnglish
Pages (from-to)243-249
Number of pages7
JournalThoracic Surgery Clinics
Issue number2
Publication statusPublished - May 2012


  • Adjuvant chemotherapy
  • Lymph node
  • Neoadjuvant chemotherapy
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Surgery


Dive into the research topics of 'The Impact of Chemotherapy on the Lymphatic System in Thoracic Oncology'. Together they form a unique fingerprint.

Cite this